Article metrics

Download PDFPDF

Original article
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

 

Online download statistics by month:

Online download statistics by month: January 2019 to May 2020

AbstractFullPdf
Jan 2019436428157
Feb 2019274266145
Mar 2019216209103
Apr 201912812473
May 201911110163
Jun 2019948363
Jul 2019989544
Aug 2019757237
Sep 2019868448
Oct 201911311163
Nov 2019777246
Dec 2019676429
Jan 2020817343
Feb 2020494416
Mar 2020575030
Apr 2020604927
May 2020514536
Total207319701023